ZTS Zoetis Inc.
USHealthcareAs of 2026-08-24
Why ZTS matters now
Zoetis Inc. (ZTS) is a US stock in Healthcare. The latest InvestLog snapshot shows $77.15 with -0.75% on the session and $32.34B in market capitalization; recent performance reads 1-month -0.27% and YTD -37.44%.
The latest financial table shown here is Q1 2026, with revenue of $2.26B, net income of $601.0M, and EPS of $1.42. Investors can compare that operating picture with valuation signals such as P/E 19.74 and FCF yield 6.5%.
InvestLog's latest related AI research is a Earnings Analysis note titled "ZTS earnings call: guidance, demand, margins, analyst Q&A". The latest indexable market news headline is "3 High-Yielding Dividend Stocks That Have Doubled Their Payouts in 5 Years" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Hold with a median target of $115.00; recent insider activity includes Nayak Abhay U filing ; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
19.74
PEG
2.62
P/B
10.28
P/S
3.47
EV/EBITDA
10.00
DCF Value
$197.35
FCF Yield
6.5%
Div Yield
2.6%
Margins & Returns
Gross Margin
70.8%
Operating Margin
37.6%
Net Margin
27.8%
ROE
62.4%
ROA
17.4%
ROIC
21.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.26B | $601.0M | $1.42 |
| Q4 2025 | $2.39B | $603.0M | $1.37 |
| FY 2025 | $9.47B | $2.67B | $6.02 |
| Q3 2025 | $2.40B | $721.0M | $1.63 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$120.80
Target (Median)
$115.00
Target Range
$95.00 - $160.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
ZTS earnings call: guidance, demand, margins, analyst Q&AZoetis Inc. (ZTS) 电话会要点:指引、需求、利润率、分析师问答
Wetteny Joseph: We are revising our full year revenue guidance to a range of $9.12 billion to $9.32 billion, representing a decline of 3% to 1% year-over-year on an organic operational basis, reflecting the continued pressure we are seeing across key Companion Animal franchises and ongoing challenges with vet clinic visits and affordability, including our gross-to-net actions to defend share.韦特尼·约瑟夫:我们将全年营收指引调整至91.2亿美元至93.2亿美元区间,按有机运营基准计算同比下降3%至1%,反映出核心伴侣动物业务板块持续承压、兽医诊所就诊和支付能力面临持续挑战,包括我们为捍卫市场份额采取的总营收净额调整措施。
ZTS earnings release — EPS beat +1.1% · revenue missed -1.3%Zoetis Inc. (ZTS) 财报发布 — EPS 高于预期+1.1% · 营收 低于预期-1.3%
Zoetis Inc. reported EPS $1.87 vs $1.85 estimate and revenue $2.5B vs $2.5B estimate.Zoetis Inc. 公布财报:EPS $1.87 vs $1.85 预期,营收 $2.5B vs $2.5B 预期。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
0.74
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.